NCT04982627: BNICHAT

A Brief Negotiation Interview Chatbot to Improve Buprenorphine Engagement Among Justice-Involved Individuals

Completed NA Last updated 3 July 2024

What this trial tests

NA trial testing BNI Chatbot in Opioid Use Disorder, Moderate in 4 participants. Completed in 1 September 2023.

Timeline

1 August 2021

Primary endpoint
31 August 2022

1 September 2023

Quick facts

Lead sponsor	Center for Progressive Recovery, LLC
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	1 August 2021
Primary completion	31 August 2022
Estimated completion	1 September 2023
Sites	1 location across United States

Drugs / interventions tested

• BNI Chatbot
• OUD Education & Treatment Resources

Conditions studied

• Opioid Use Disorder, Moderate — all drugs for Opioid Use Disorder, Moderate →
• Opioid Use Disorder, Severe — all drugs for Opioid Use Disorder, Severe →
• Criminal Behavior — all drugs for Criminal Behavior →

Sponsor

Center for Progressive Recovery, LLC

Who can join

Adults 18 to 65, any sex, with Opioid Use Disorder, Moderate or Opioid Use Disorder, Severe. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary Objective:

Conduct pilot study to assess effects of brief negotiation interview (BNI) Chatbot among individuals involved in the Connecticut criminal justice system with opioid use disorder (OUD).

Study Duration:

Approximately 2 years (1 year for study activities, 1 year for data analysis)

Study Design:

This is a prospective, randomized study to evaluate the effectiveness of a BNI Chatbot on patients with OUD compared with Standard Care (SC).

Number of Study Sites:

The offices of the Center for Progressive Recovery, LLC and the New Haven Police Department Detention Center (NHPD).

Study Population:

The study population includes adult individuals with OUD who are involved in the Connecticut criminal justice system and not currently receiving medication-assisted treatment for their OUD.

Number of Participants:

Sixty participants

Primary Outcome Variable:

Attendance at participants first treatment appointment within four weeks of referral among participants in the BNI Chatbot vs. Standard Care (SC) groups.

Secondary Outcome and Exploratory Outcome Variables:

Secondary outcomes include readiness and intention to engage in buprenorphine (bup) treatment, and urine toxicology test-confirmed drug use at four weeks among participants in BNI Chatbot vs. SC groups. Exploratory outcomes include ratings of feasibility, acceptability and satisfaction between study groups, and a comparison of study findings to engagement data from previous in-person studies, including BNI+bup, and other digital programs, such as reSET-O, and DynamiCare.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.